DK164485C - Polymerholdige medikamenter, fremgangsmaade til fremstilling heraf samt farmaceutisk praeparat indeholdende mindst et saadant medikament - Google Patents
Polymerholdige medikamenter, fremgangsmaade til fremstilling heraf samt farmaceutisk praeparat indeholdende mindst et saadant medikamentInfo
- Publication number
- DK164485C DK164485C DK003386A DK3386A DK164485C DK 164485 C DK164485 C DK 164485C DK 003386 A DK003386 A DK 003386A DK 3386 A DK3386 A DK 3386A DK 164485 C DK164485 C DK 164485C
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- mol
- units derived
- bound
- methacryloylated
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000000975 bioactive effect Effects 0.000 abstract 2
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical compound NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 abstract 1
- 238000004166 bioassay Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8500209 | 1985-01-04 | ||
| GB858500209A GB8500209D0 (en) | 1985-01-04 | 1985-01-04 | Synthetic polymeric drugs |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| DK3386D0 DK3386D0 (da) | 1986-01-03 |
| DK3386A DK3386A (da) | 1986-07-05 |
| DK164485B DK164485B (da) | 1992-07-06 |
| DK164485C true DK164485C (da) | 1992-11-23 |
Family
ID=10572420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK003386A DK164485C (da) | 1985-01-04 | 1986-01-03 | Polymerholdige medikamenter, fremgangsmaade til fremstilling heraf samt farmaceutisk praeparat indeholdende mindst et saadant medikament |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5037883A (de) |
| EP (1) | EP0187547B1 (de) |
| JP (2) | JPH075474B2 (de) |
| AT (1) | ATE60991T1 (de) |
| AU (1) | AU589587B2 (de) |
| CA (1) | CA1305053C (de) |
| DE (1) | DE3581921D1 (de) |
| DK (1) | DK164485C (de) |
| GB (1) | GB8500209D0 (de) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4738434A (en) | 1986-04-07 | 1988-04-19 | Marjoram Robert H | Vibration and/or shock attenuating fluid mount or the like |
| JP2896580B2 (ja) * | 1989-08-25 | 1999-05-31 | チッソ株式会社 | アミロース―リゾチームハイブリッドと活性化糖およびその製造法 |
| DE69120141T2 (de) * | 1990-03-28 | 1996-11-28 | Shuji Kojima | Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| CZ2190U1 (cs) * | 1991-02-01 | 1994-07-14 | Alexandr Rndr. Csc. Jegorov | Směrované polymerní konjugáty cyklosporinu |
| US5332575A (en) * | 1991-10-03 | 1994-07-26 | Parfums Christian Dior | Method of targeting melanocytes with a compound containing a fucose residue |
| US5258453A (en) * | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| GB2270920B (en) * | 1992-09-25 | 1997-04-02 | Univ Keele | Alginate-bioactive agent conjugates |
| US7056935B2 (en) | 1995-06-07 | 2006-06-06 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| GB9600471D0 (en) * | 1996-01-10 | 1996-03-13 | Univ London Pharmacy | Drug delivery system |
| GB9606975D0 (en) * | 1996-04-02 | 1996-06-05 | Univ Birmingham | Anti-tumor agent |
| EP0895784B1 (de) | 1996-04-15 | 2005-11-23 | Asahi Kasei Kabushiki Kaisha | Arzneimittelkomplexe enthaltend taxan-verbindungen oder steroiden |
| WO1998047496A2 (en) * | 1997-04-18 | 1998-10-29 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
| US5965118A (en) * | 1997-04-18 | 1999-10-12 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
| US6251866B1 (en) | 1997-08-05 | 2001-06-26 | Watson Laboratories, Inc. | Conjugates targeted to the interleukin-2 receptor |
| US6180084B1 (en) * | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
| US6066673A (en) * | 1998-03-12 | 2000-05-23 | The Procter & Gamble Company | Enzyme inhibitors |
| US7018654B2 (en) | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| AU1820400A (en) * | 1999-11-17 | 2001-05-30 | School Of Pharmacy, University Of London, The | Conjugates of hpma copolymer and ellipticin |
| DK1257269T3 (da) | 2000-02-24 | 2005-03-14 | Kopran Res Lab Ltd | Syrestabile benzimidazolderivater til oral indgivelse mod ulcus |
| DE60131177T2 (de) | 2000-09-06 | 2008-08-07 | AP Pharma, Inc., Redwood | Abbaubare polyacetal-polymere |
| US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
| WO2002090390A1 (en) * | 2001-05-04 | 2002-11-14 | University Of Utah Research Foundation | Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells |
| US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US7338939B2 (en) | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
| US20030124742A1 (en) * | 2001-08-22 | 2003-07-03 | Prakash Ramesh K. | Conjugates targeted to target receptors |
| US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| CZ293787B6 (cs) * | 2001-12-20 | 2004-07-14 | Zentiva, A.S. | pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii |
| CA2477004C (en) | 2002-02-22 | 2011-05-10 | Thomas Piccariello | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| JP4514455B2 (ja) * | 2002-04-11 | 2010-07-28 | チルドレンズ メディカル センター コーポレーション | Ｔｎｐ−４７０ポリマー複合体及びその使用 |
| WO2003086178A2 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| US20050169883A1 (en) * | 2002-05-06 | 2005-08-04 | Prestwich Glenn D. | Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| US20040116348A1 (en) * | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
| US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
| WO2004082718A1 (ja) * | 2003-03-20 | 2004-09-30 | Nippon Kayaku Kabushiki Kaisha | 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 |
| ATE459647T1 (de) | 2003-04-15 | 2010-03-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
| AU2004251647B2 (en) | 2003-05-29 | 2010-01-14 | Takeda Pharmaceutical Company Limited | Abuse resistant amphetamine compounds |
| BRPI0414876A (pt) | 2003-09-30 | 2006-11-21 | New River Pharmaceuticals Inc | compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos |
| BR122018071808B8 (pt) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| CA2557448C (en) * | 2004-03-31 | 2015-06-23 | University Of Utah Research Foundation | Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases |
| KR101203475B1 (ko) * | 2004-09-22 | 2012-11-21 | 니폰 가야꾸 가부시끼가이샤 | 신규 블록 공중합체, 미셀 제제물 및 이를 유효성분으로함유하는 항암제 |
| CN101106974B (zh) | 2005-01-14 | 2012-08-08 | 韩国科学技术研究院 | 形成自聚集体的胆甾烷酸-脱乙酰壳多糖复合物及其制备方法 |
| WO2006084054A2 (en) * | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
| KR20080106254A (ko) | 2006-03-28 | 2008-12-04 | 니폰 가야꾸 가부시끼가이샤 | 탁산류의 고분자 결합체 |
| US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
| WO2007143209A2 (en) * | 2006-06-02 | 2007-12-13 | University Of Virginia Patent Foundation | Luminescent diketonate polymers |
| JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
| EP2080779B1 (de) | 2006-11-06 | 2016-05-18 | Nippon Kayaku Kabushiki Kaisha | Polymeres derivat eines nucleinsäuremetabolismus-antagonisten |
| JP5548365B2 (ja) | 2006-11-08 | 2014-07-16 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
| CN1973902B (zh) * | 2006-12-12 | 2010-11-10 | 东北师范大学 | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 |
| JP5349318B2 (ja) | 2007-09-28 | 2013-11-20 | 日本化薬株式会社 | ステロイド類の高分子結合体 |
| EP2258397B1 (de) * | 2008-03-18 | 2017-10-11 | Nippon Kayaku Kabushiki Kaisha | Polymerkonjugat aus einem physiologisch aktiven stoff |
| WO2009136572A1 (ja) | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
| BRPI0920655A2 (pt) * | 2008-10-07 | 2019-07-09 | Rexahn Pharmaceuticals Inc | conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos |
| CN102421827B (zh) | 2009-05-15 | 2014-07-30 | 日本化药株式会社 | 具有羟基的生理活性物质的高分子结合体 |
| AU2010306917B2 (en) | 2009-10-13 | 2014-11-27 | Rexahn Pharmaceuticals, Inc. | Polymeric systems for the delivery of anticancer agents |
| CZ302830B6 (cs) | 2009-12-15 | 2011-11-30 | Ústav makromolekulární chemie AV CR, v.v.i. | Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru |
| WO2011112482A2 (en) | 2010-03-08 | 2011-09-15 | University Of Utah Research Foundation | Polymeric drug delivery conjugates and methods of making and using thereof |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| DK2576638T3 (da) | 2010-05-25 | 2021-03-15 | Syndevrx Inc | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
| EP2641605B1 (de) | 2010-11-17 | 2018-03-07 | Nippon Kayaku Kabushiki Kaisha | Polymerderivat für einen cytidinstoffwechselantagonisten |
| CA2827029C (en) | 2011-02-11 | 2019-07-02 | The Regents Of The University Of Michigan | Tripeptide compositions and methods |
| EP2754682B1 (de) | 2011-09-11 | 2017-06-07 | Nippon Kayaku Kabushiki Kaisha | Verfahren zur herstellung von blockcopolymer |
| ES2784182T3 (es) | 2013-03-12 | 2020-09-22 | Univ Utah Res Found | Composiciones y métodos para inducir la apoptosis |
| MX371095B (es) | 2013-04-10 | 2020-01-16 | Syndevrx Inc | Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. |
| CN103965398B (zh) * | 2014-04-11 | 2016-04-13 | 西北师范大学 | D-半乳糖/苯甲醛氮芥/n-(2-羟丙基)甲基丙烯酰胺共聚物及其制备和应用 |
| ES2893749T3 (es) | 2015-12-10 | 2022-02-10 | Syndevrx Inc | Derivados de fumagilol y polimorfos de los mismos |
| WO2017123603A1 (en) | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| WO2018118903A1 (en) | 2016-12-19 | 2018-06-28 | The Regents Of The University Of California | Noncrushable pill formulatiions |
| WO2018118902A1 (en) | 2016-12-19 | 2018-06-28 | The Regents Of The University Of California | Dual-enzyme responsive peptides |
| JP7136807B2 (ja) | 2017-04-17 | 2022-09-13 | ザ・ユニバーシティ・オブ・シカゴ | ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料 |
| US10894019B2 (en) | 2017-08-15 | 2021-01-19 | University Of South Carolina | Drug delivery system and method for targeting cancer stem cells |
| EP3870231A1 (de) | 2018-10-26 | 2021-09-01 | Syndevrx, Inc. | Biomarker von metap2-inhibitoren und anwendungen davon |
| US11672767B2 (en) | 2019-05-13 | 2023-06-13 | University Of South Carolina | Enzymatically cleavable self-assembled nanoparticles for morphogen delivery |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL133221C (de) * | 1965-11-12 | |||
| US3957700A (en) * | 1972-05-04 | 1976-05-18 | British Industrial Plastics Limited | Filled aminoplast moulding materials |
| US4007142A (en) * | 1974-04-24 | 1977-02-08 | Balm Paints Limited | Amine resin and process |
| GB8311136D0 (en) * | 1983-04-25 | 1983-06-02 | Lepetit Spa | Immobilised oligopeptides |
-
1985
- 1985-01-04 GB GB858500209A patent/GB8500209D0/en active Pending
- 1985-12-31 EP EP85309560A patent/EP0187547B1/de not_active Expired - Lifetime
- 1985-12-31 AT AT85309560T patent/ATE60991T1/de not_active IP Right Cessation
- 1985-12-31 DE DE8585309560T patent/DE3581921D1/de not_active Expired - Lifetime
-
1986
- 1986-01-03 AU AU51833/86A patent/AU589587B2/en not_active Ceased
- 1986-01-03 CA CA000498931A patent/CA1305053C/en not_active Expired - Lifetime
- 1986-01-03 DK DK003386A patent/DK164485C/da not_active IP Right Cessation
- 1986-01-04 JP JP61000137A patent/JPH075474B2/ja not_active Expired - Fee Related
-
1989
- 1989-11-17 US US07/438,352 patent/US5037883A/en not_active Expired - Lifetime
-
1994
- 1994-05-31 JP JP6140759A patent/JP2620517B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK3386A (da) | 1986-07-05 |
| ATE60991T1 (de) | 1991-03-15 |
| DE3581921D1 (de) | 1991-04-04 |
| JPS61243026A (ja) | 1986-10-29 |
| AU5183386A (en) | 1986-07-10 |
| GB8500209D0 (en) | 1985-02-13 |
| CA1305053C (en) | 1992-07-14 |
| US5037883A (en) | 1991-08-06 |
| JPH07300428A (ja) | 1995-11-14 |
| AU589587B2 (en) | 1989-10-19 |
| JP2620517B2 (ja) | 1997-06-18 |
| DK164485B (da) | 1992-07-06 |
| JPH075474B2 (ja) | 1995-01-25 |
| EP0187547B1 (de) | 1991-02-27 |
| EP0187547A3 (en) | 1987-07-22 |
| DK3386D0 (da) | 1986-01-03 |
| EP0187547A2 (de) | 1986-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK164485C (da) | Polymerholdige medikamenter, fremgangsmaade til fremstilling heraf samt farmaceutisk praeparat indeholdende mindst et saadant medikament | |
| DK0693924T4 (da) | Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil | |
| KR960702323A (ko) | 폴리머를 사용하는 비타민 b₁₂ 흡수시스템의 증폭 (amplification of the vitamin b₁₂ uptake system using polymers) | |
| DE3687458D1 (de) | Filmbildende arzneimitteltraeger zur verabreichung von arzneimitteln an naegeln | |
| BR9713486A (pt) | Preparações farmacêuticas compreendidas de sais de ácido hialurÈnico com anestésicosm locais. | |
| IL109403A0 (en) | Oral drug delivery compositions and methods | |
| ATE67930T1 (de) | Wirkstofftraeger und diesen enthaltende arzneimittel. | |
| ATE206716T1 (de) | Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität | |
| PT666914E (pt) | Nova proteina ligando da selectina p | |
| ATE199377T1 (de) | Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung | |
| PT998501E (pt) | Polimeros cationicos complexos associando os referidos polimeros cationicos e substancias terapeuticamente activas compreendendo pelo menos uma carga negativa especialmente acidos nucleicos e sua utilizacao em terapia genica | |
| ES2171086T3 (es) | Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica. | |
| ES2111653T3 (es) | Gen que codifica la heparinasa de flavobacterium heparinum. | |
| ES2144418T3 (es) | Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario. | |
| ES2133295T3 (es) | Peptidos ciclicos y su uso. | |
| IL79816A (en) | Pharmaceutical compositions comprising a drug-polymer matrix | |
| DK0707473T3 (da) | Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler | |
| ATE89317T1 (de) | Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten. | |
| ITMI911950A1 (it) | Sistema terapeutico transdermale per la somministrazione di farmaci ad attivita' broncodilatante. | |
| DE68906572D1 (de) | Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| KR930004326A (ko) | 콘드로모듈린-ii 단백질 | |
| FI962985A (fi) | Oraalinen lääkemuoto, jossa on happamia vaikuttavia aineita, ja menetelmä sen valmistamiseksi | |
| DK328189D0 (da) | Konjugater mellem et laegemiddel og en nitrophenylgruppe samt farmaceutisk anvendelse deraf | |
| DE68909451D1 (de) | Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| ISHIDATE | Symposium:" Cancer Chemotherapy" Some Aspects of the Reaction Mechanism of Nitrogen Mustard and its N-oxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |
Country of ref document: DK |